Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday, Benzinga reports.
Separately, Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.
View Our Latest Stock Analysis on Clene
Clene Stock Up 8.7%
Shares of NASDAQ CLNN traded up $0.27 during trading hours on Monday, hitting $3.37. The company had a trading volume of 31,980 shares, compared to its average volume of 220,563. The stock has a market capitalization of $43.76 million, a P/E ratio of -0.96 and a beta of 0.91. Clene has a 1-year low of $3.02 and a 1-year high of $13.50. The firm’s 50 day moving average is $4.04 and its 200-day moving average is $5.33.
Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.06 million. On average, sell-side analysts predict that Clene will post -1.70 earnings per share for the current year.
Clene Company Profile
Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.
Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.
Featured Stories
- Five stocks we like better than Clene
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
- Rate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging
- The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
- 5 Beaten-Down AI Names That Could Bounce If Fear Fades
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
